Trial Profile
Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2015
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Pharmacodynamics; Therapeutic Use
- 07 Sep 2015 New trial record
- 27 Aug 2015 Results published in the Thrombosis and Haemostasis.